Corvidia Therapeutics Secures $26,000,000 Series A Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=83cefcb0-e4a4-45c7-80cc-897e2ec72b3e
Date
2/18/2016
Company Name
Corvidia Therapeutics
Mailing Address
35 Gatehouse Drive Waltham, MA 02451 USA
Company Description
Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company’s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations.
Website
http://www.corvidiatx.com
Transaction Type
Venture Equity
Transaction Amount
$26,000,000
Transaction Round
Series A
Proceeds Purposes
Funds from the Series A financing will be used to progress COR-001 into Phase I/II clinical trials during 2016, as well as to advance the company’s preclinical pipeline.
M&A Terms
Venture Investor
Apple Tree Partners
Venture Investor
Sofinnova Ventures
Venture Investor
Investor